Thursday, September 17, 2026RSS
Peptide.Wire

The daily wire on therapeutic peptides. Regulatory, research, compounding and the incretin race, condensed.

Regulatorybpc-157retatrutidept-141gray marketresearch use only

WIRED lab tests find no active ingredient in bodega-bought BPC-157, retatrutide vials

Four vials bought for $376.20 at a Brooklyn shop contained low heavy metals and endotoxins but none of the labeled peptides.

DO
By Daniel Okafor · Regulatory Correspondent
Sep 15 06:30 ETSource: WIRED

The wire

  1. 01WIRED bought PT-141, BPC-157, NAD+ and retatrutide vials from vendor INDR Labs at a Bedford Avenue bodega and sent them to testing startup Finnrick; none contained the active ingredient on the label.
  2. 02The vials were sold as 'research use only' and handed over in an unlabeled paper bag, illustrating the gray-market supply risk clinicians and patients face outside 503A and 503B channels.
  3. 03The lab chief executive says the analysis only verifies label claims, so what the vials actually contained is unknown; degradation from improper storage is one possible explanation.

From the source

Those Viral Bodega Peptides Aren’t Actually Peptides

The Mr. Green bodega sits on a busy stretch of Bedford Avenue in Brooklyn, New York. Near the counter, you can buy the usual assortment of candy, gum, rolling papers, and soda. You can also purchase tiny vials of injectable peptides . So we did. And then we sent them to a lab.

Read at wired.com